E.g., 05/21/2019
E.g., 05/21/2019

Webinar (hosted by CIDRAP): Value of Diagnostics to Enhance Antimicrobial Stewardship

16 May, 2019

bioMérieux is proud to announce an educational Webinar hosted by CIDRAP (Center for Infectious Disease Research and Policy) as part of its Antimicrobial Stewardship Project (ASP): Value of Diagnostics to Enhance Antimicrobial Stewardship

bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical

05 April, 2018

Marcy l’Étoile, France – April 4th, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers. In particular, Astute developed the NEPHROCHECK® test, an FDA-cleared test for the early risk assessment of acute kidney injuries (AKI) based on the level of two biomarkers, IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7) and TIMP-2 (Tissue Inhibitor Metalloproteinases-2).

Pioneering diagnostics